Sequence-specific in vivo cell targeting
US11491208B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 25, 2020 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | Sep 25, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.